Kisspeptin: a potential therapeutic target in patients with unexplained infertility

Basit Öğe Kaydı
dc.contributor.authorAtakul, Nil
dc.contributor.authorKilic, Berna Sermin
dc.contributor.authorSelek, Sahabettin
dc.contributor.authorAtamer, Yildiz
dc.contributor.authorUnal, Fehmi
dc.date.accessioned2024-03-13T10:30:52Z
dc.date.available2024-03-13T10:30:52Z
dc.date.issued2023
dc.departmentİstanbul Beykent Üniversitesien_US
dc.description.abstractBackground Kisspeptin has recently emerged as a key regulator of the reproductive axis in women. Kisspeptin, acting centrally via the kisspeptin receptor, stimulates the secretion of the gonadotrophin-releasing hormone (GnRH). Aims To investigate serum kisspeptin levels in infertility patients for its clinical utilisation in management and understanding of the pathophysiology of infertility in a wide array of patients. Methods This prospective case-control study analysis involved 92 primary infertile women with PCOS, diminished ovarian reserve (DOR), unexplained infertility (UEI), and male factor infertility between 20 and 42 years of age. Serum samples were collected between the second and fifth day of the menstrual cycle. The kisspeptin level was determined using a human kisspeptin ELISA kit according to the manufacturer's procedure. Results The median value of serum kisspeptin in the PCOS infertility group was significantly higher than that in the UEI group (p = 0.011). There was a statistically significant (p = 0.015, r = -0.182) negative weak correlation found between serum kisspeptin levels and age. The optimal cutoff value obtained to differentiate the UEI from others (PCOS infertility + DOR + male factor infertility) according to the serum kisspeptin level was 214.3 ng/L with a sensitivity of 55% and specificity of 80.9%. Conclusions Understanding the role of kisspeptin may lead to its use as a biomarker in infertility diagnosis in UEI patients and might guide the use of kisspeptin analogues in selected patients for infertility management.en_US
dc.identifier.doi10.1007/s11845-022-03152-1
dc.identifier.endpage1784en_US
dc.identifier.issn0021-1265
dc.identifier.issn1863-4362
dc.identifier.issue4en_US
dc.identifier.pmid36114933en_US
dc.identifier.scopus2-s2.0-85138232730en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1779en_US
dc.identifier.urihttps://doi.org/10.1007/s11845-022-03152-1
dc.identifier.urihttps://hdl.handle.net/20.500.12662/3569
dc.identifier.volume192en_US
dc.identifier.wosWOS:000854833500001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer London Ltden_US
dc.relation.ispartofIrish Journal Of Medical Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDiminished ovarian reserveen_US
dc.subjectKisspeptinen_US
dc.subjectPolycystic ovarian syndrome (PCOS)en_US
dc.subjectUnexplained infertilityen_US
dc.titleKisspeptin: a potential therapeutic target in patients with unexplained infertilityen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu